Antiretroviral therapy during pregnancy and early neonatal life: consequences for HIV-exposed, uninfected children
Braz. j. infect. dis
; Braz. j. infect. dis;8(2): 140-150, Apr. 2004.
Article
em En
| LILACS
| ID: lil-365407
Biblioteca responsável:
BR1.1
RESUMO
Women have emerged as the fastest growing human immunodeficiency virus (HIV) infected population worldwide, mainly because of the increasing occurrence of heterosexual transmission. Most infected women are of reproductive age and one of the greatest concerns for both women and their physicians is that more than 1,600 infants become infected with HIV each day. Almost all infections are a result of mother-to-child transmission of HIV. With the advent of combination antiretroviral therapies, transmission rates lower than 2 percent have been achieved in clinical studies. Antiretroviral compounds differ from most other new pharmaceutical agents in that they have become widely prescribed in pregnancy in the absence of proof of safety. We reviewed antiretroviral agents used in pregnant women infected with human immunodeficiency virus, mother-to-child transmission, and their consequences for infants.
Texto completo:
1
Índice:
LILACS
Assunto principal:
Complicações Infecciosas na Gravidez
/
Infecções por HIV
/
Transmissão Vertical de Doenças Infecciosas
/
Fármacos Anti-HIV
Limite:
Female
/
Humans
/
Newborn
/
Pregnancy
Idioma:
En
Revista:
Braz. j. infect. dis
Assunto da revista:
DOENCAS TRANSMISSIVEIS
Ano de publicação:
2004
Tipo de documento:
Article